Vaxneuvance, Prevnar 20 Earn CDC Cmte Nod For Age- And Risk-Based Use; Broader Shingrix Use Supported
Executive Summary
ACIP votes unanimously to recommend Merck and Pfizer’s pneumococcal vaccines in elderly and immunocompromised adults; GSK’s herpes zoster vaccine also gets unanimous nod for immunocompromised adults.
You may also be interested in...
US CDC Panel’s Pneumococcal Vaccine Recommendations Leave Confusion In Their Wake
Advisory Committee on Immunization Practices’ October vote on use of Pfizer’s Prevnar 20 and Merck & Co’s Vaxneuvance was more restrictive than intended, inadvertently leaving out guidance for people who were previously vaccinated with Prevnar 13.
Bad Times For Breakthrough Drugs Targeting Chemo Complications; Submissions From BMS, Merck
The latest news about applications under FDA review, from the Pink Sheet’s US FDA Performance Tracker
Pneumococcal Vaccines Market Snapshot: Pfizer And Merck Face Off
Pfizer's Prevnar 20 and Merck's Vaxneuvance are launching simultaneously and are expected to help drive vaccines growth for both big pharmas.